<DOC>
	<DOCNO>NCT01634568</DOCNO>
	<brief_summary>A double-blind , randomise , placebo-controlled study safety , tolerability pharmacokinetics single multiple ascend oral dos V81444 healthy male volunteer</brief_summary>
	<brief_title>A Clinical Trial Find Out V81444 's Side Effects Blood Levels Healthy Men</brief_title>
	<detailed_description>Part A - Single Ascending Dose ( SAD ) Double-blind , randomise , placebo-controlled , single ascend dose study . Each study subject participate screen visit , three identical treatment period , receive single oral dose V81444 placebo accord-ance randomisation schedule , one post-study visit . In treatment period , subject admit day dose ( Day -1 ) , subject satisfactory medical review , discharge morning , 4 day later ( Day 4 ) . Part B - Multiple Ascending Dose ( MAD ) Double-blind , randomise , placebo-controlled , parallel group , multiple ascend dose study Each study subject participate screen visit , one treatment period receive repeat oral dos V81444 placebo accordance randomisation schedule , one post-study visit . In treatment period , subject admit day dose ( Day -1 ) , dose daily Days 1 14 , subject satisfactory medical review , discharge morning , 3 day final dose ( Day 17 ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Healthy male volunteer : age 18 45 year , good general health determine medical history , physical examination screen investigation , take regular medication . Confirmation seek volunteer general practitioner provide acceptable medical history . history evidence clinically significant gastrointestinal disease , include ulcer , gastrooesophageal reflux disease gastritis know malformation would make OGD difficult unsafe ( Part B ) take V81444 previous investigational study take restrict concomitant medication multiple drug allergy allergic component V81444 study medication match placebo midazolam ( Part B ) 4 calendar month study drug administration smoke 5 cigarette per day consume 28 unit alcohol per week donate blood plasma excess 500 mL expose new investigational agent adenosine A2A receptor antagonist use nonsteroidal antiinflammatory drug regularly new tattoo body pierce clinically relevant abnormal finding screen and/or admission intend father child female partner sperm donation within 4 month last dose study medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>